Cara Therapeutics, Inc. (NASDAQ:CARA) Receives Consensus Rating of “Hold” from Brokerages

Cara Therapeutics, Inc. (NASDAQ:CARA) has been assigned an average rating of “Hold” from the five research firms that are covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating. The average 12-month price objective among brokerages that have covered the stock in the last year is $27.84.

Separately, StockNews.com initiated coverage on Cara Therapeutics in a research report on Wednesday, January 8th. They set a “sell” rating for the company.

Cara Therapeutics Price Performance

Shares of NASDAQ CARA opened at $5.23 on Friday. The business’s 50 day moving average is $4.96 and its two-hundred day moving average is $4.17. Cara Therapeutics has a 1-year low of $2.71 and a 1-year high of $11.52. The stock has a market capitalization of $23.92 million, a P/E ratio of -0.25 and a beta of 0.50.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. FMR LLC boosted its holdings in shares of Cara Therapeutics by 18.5% in the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 32,789 shares during the period. Curi RMB Capital LLC purchased a new stake in shares of Cara Therapeutics in the fourth quarter valued at approximately $277,000. Shay Capital LLC purchased a new stake in shares of Cara Therapeutics in the fourth quarter valued at approximately $524,000. XTX Topco Ltd purchased a new stake in shares of Cara Therapeutics in the third quarter valued at approximately $29,000. Finally, Rockefeller Capital Management L.P. purchased a new stake in shares of Cara Therapeutics in the fourth quarter valued at approximately $953,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.